English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Brodalumab, a human monoclonal anti-interleukin (IL)17 receptor A antibody, is used to treat patients with moderate-to-severe plaque psoriasis in the USA and Europe. In Japan it is also indicated for use in treatment of pustular psoriasis and psoriatic erythroderma (1). Common side-effects of brodalumab include headache, arthralgia, myalgia, fatigue, diarrhoea, superficial fungal infections, and neutropaenia. We report here a case of pustular psoriasis complicated with pleural fluid eosinophilia (PFE) following the consecutive administration of brodalumab.

Pleural Fluid Eosinophilia: a Possible Adverse Event of Interrleukin-17 Inhibition